ACHN has completed Phase 1a of ACH-1625, a protease inhibitor for the treatment of HCV infection, and has begun dosing HCV-infected patients in the Phase 1b segment of the trial. ACH-1625 was safe and well-tolerated in both the single and the multiple ascending dose segments.
Market Data 
Markets 
AI
